Sanofi, in collaboration with Regeneron, has launched Phase 3 trial to assess Itepekimab in Japanese adults with inadequately-controlled chronic rhinosinusitis with nasal polyps.

ClinicalJune 23, 2026

Sanofi and Regeneron Launch Phase 3 Study on Itepekimab for Chronic Rhinosinusitis

A Phase 3 extension study has been initiated to assess the long-term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

(1)

Topline Data

Sanofi — Itepekimab

June 23, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Anti-IL-33 mAb →

Chronic Rhinosinusitis with Nasal Polyps →

Otolaryngology →

Otolaryngology · Chronic Rhinosinusitis with Nasal Polyps →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.